275 related articles for article (PubMed ID: 30371656)
21. Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint antibody therapy in mice.
Smith JP; Wang S; Nadella S; Jablonski SA; Weiner LM
Cancer Immunol Immunother; 2018 Feb; 67(2):195-207. PubMed ID: 29043413
[TBL] [Abstract][Full Text] [Related]
22. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.
Pu N; Zhao G; Yin H; Li JA; Nuerxiati A; Wang D; Xu X; Kuang T; Jin D; Lou W; Wu W
J Transl Med; 2018 Oct; 16(1):294. PubMed ID: 30359281
[TBL] [Abstract][Full Text] [Related]
23. Antitumor T-cell Immunity Contributes to Pancreatic Cancer Immune Resistance.
Ajina R; Malchiodi ZX; Fitzgerald AA; Zuo A; Wang S; Moussa M; Cooper CJ; Shen Y; Johnson QR; Parks JM; Smith JC; Catalfamo M; Fertig EJ; Jablonski SA; Weiner LM
Cancer Immunol Res; 2021 Apr; 9(4):386-400. PubMed ID: 33509790
[TBL] [Abstract][Full Text] [Related]
24. JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice.
Song X; Zhu S; Xie Y; Liu J; Sun L; Zeng D; Wang P; Ma X; Kroemer G; Bartlett DL; Billiar TR; Lotze MT; Zeh HJ; Kang R; Tang D
Gastroenterology; 2018 Apr; 154(5):1480-1493. PubMed ID: 29248440
[TBL] [Abstract][Full Text] [Related]
25. Mouse-Derived Allografts: A Complementary Model to the KPC Mice on Researching Pancreatic Cancer In Vivo.
Li J; Qian W; Qin T; Xiao Y; Cheng L; Cao J; Chen X; Ma Q; Wu Z
Comput Struct Biotechnol J; 2019; 17():498-506. PubMed ID: 31011408
[TBL] [Abstract][Full Text] [Related]
26. Disruption of C1galt1 Gene Promotes Development and Metastasis of Pancreatic Adenocarcinomas in Mice.
Chugh S; Barkeer S; Rachagani S; Nimmakayala RK; Perumal N; Pothuraju R; Atri P; Mahapatra S; Thapa I; Talmon GA; Smith LM; Yu X; Neelamegham S; Fu J; Xia L; Ponnusamy MP; Batra SK
Gastroenterology; 2018 Nov; 155(5):1608-1624. PubMed ID: 30086262
[TBL] [Abstract][Full Text] [Related]
27. Radiation Therapy Induces Macrophages to Suppress T-Cell Responses Against Pancreatic Tumors in Mice.
Seifert L; Werba G; Tiwari S; Giao Ly NN; Nguy S; Alothman S; Alqunaibit D; Avanzi A; Daley D; Barilla R; Tippens D; Torres-Hernandez A; Hundeyin M; Mani VR; Hajdu C; Pellicciotta I; Oh P; Du K; Miller G
Gastroenterology; 2016 Jun; 150(7):1659-1672.e5. PubMed ID: 26946344
[TBL] [Abstract][Full Text] [Related]
28. A novel anti-galectin-9 immunotherapy limits the early progression of pancreatic neoplastic lesions in transgenic mice.
Quilbe A; Mustapha R; Duchêne B; Kumar A; Werkmeister E; Leteurtre E; Moralès O; Jonckheere N; Van Seuningen I; Delhem N
Front Immunol; 2023; 14():1267279. PubMed ID: 38098486
[TBL] [Abstract][Full Text] [Related]
29.
Maddalena M; Mallel G; Nataraj NB; Shreberk-Shaked M; Hassin O; Mukherjee S; Arandkar S; Rotkopf R; Kapsack A; Lambiase G; Pellegrino B; Ben-Isaac E; Golani O; Addadi Y; Hajaj E; Eilam R; Straussman R; Yarden Y; Lotem M; Oren M
Proc Natl Acad Sci U S A; 2021 Jun; 118(23):. PubMed ID: 34088837
[TBL] [Abstract][Full Text] [Related]
30. Interleukin-1β-induced pancreatitis promotes pancreatic ductal adenocarcinoma via B lymphocyte-mediated immune suppression.
Takahashi R; Macchini M; Sunagawa M; Jiang Z; Tanaka T; Valenti G; Renz BW; White RA; Hayakawa Y; Westphalen CB; Tailor Y; Iuga AC; Gonda TA; Genkinger J; Olive KP; Wang TC
Gut; 2021 Feb; 70(2):330-341. PubMed ID: 32393543
[TBL] [Abstract][Full Text] [Related]
31. Genetically induced pancreatic adenocarcinoma is highly immunogenic and causes spontaneous tumor-specific immune responses.
Garbe AI; Vermeer B; Gamrekelashvili J; von Wasielewski R; Greten FR; Westendorf AM; Buer J; Schmid RM; Manns MP; Korangy F; Greten TF
Cancer Res; 2006 Jan; 66(1):508-16. PubMed ID: 16397267
[TBL] [Abstract][Full Text] [Related]
32. Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model.
Lau SP; van Montfoort N; Kinderman P; Lukkes M; Klaase L; van Nimwegen M; van Gulijk M; Dumas J; Mustafa DAM; Lievense SLA; Groeneveldt C; Stadhouders R; Li Y; Stubbs A; Marijt KA; Vroman H; van der Burg SH; Aerts J; van Hall T; Dammeijer F; van Eijck CHJ
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690771
[TBL] [Abstract][Full Text] [Related]
33. Establishment and characterization of a novel murine model of pancreatic cancer cachexia.
Michaelis KA; Zhu X; Burfeind KG; Krasnow SM; Levasseur PR; Morgan TK; Marks DL
J Cachexia Sarcopenia Muscle; 2017 Oct; 8(5):824-838. PubMed ID: 28730707
[TBL] [Abstract][Full Text] [Related]
34. A Novel Immunocompetent Mouse Model of Pancreatic Cancer with Robust Stroma: a Valuable Tool for Preclinical Evaluation of New Therapies.
Majumder K; Arora N; Modi S; Chugh R; Nomura A; Giri B; Dawra R; Ramakrishnan S; Banerjee S; Saluja A; Dudeja V
J Gastrointest Surg; 2016 Jan; 20(1):53-65; discussion 65. PubMed ID: 26582596
[TBL] [Abstract][Full Text] [Related]
35. Pancreatic Premalignant Lesions Secrete Tissue Inhibitor of Metalloproteinases-1, Which Activates Hepatic Stellate Cells Via CD63 Signaling to Create a Premetastatic Niche in the Liver.
Grünwald B; Harant V; Schaten S; Frühschütz M; Spallek R; Höchst B; Stutzer K; Berchtold S; Erkan M; Prokopchuk O; Martignoni M; Esposito I; Heikenwalder M; Gupta A; Siveke J; Saftig P; Knolle P; Wohlleber D; Krüger A
Gastroenterology; 2016 Nov; 151(5):1011-1024.e7. PubMed ID: 27506299
[TBL] [Abstract][Full Text] [Related]
36. Intraepithelial Attack Rather than Intratumorally Infiltration of CD8+T Lymphocytes is a Favorable Prognostic Indicator in Pancreatic Ductal Adenocarcinoma.
Zhang J; Wang YF; Wu B; Zhong ZX; Wang KX; Yang LQ; Wang YQ; Li YQ; Gao J; Li ZS
Curr Mol Med; 2017; 17(10):689-698. PubMed ID: 29521231
[TBL] [Abstract][Full Text] [Related]
37. Dynamics of intestinal and intratumoral microbiome signatures in genetically engineered mice and human pancreatic ductal adenocarcinoma.
Pfisterer N; Ammer-Herrmenau C; Antweiler K; Küffer S; Ellenrieder V; Neesse A
Pancreatology; 2023 Sep; 23(6):663-673. PubMed ID: 37541802
[TBL] [Abstract][Full Text] [Related]
38. Plasminogen deficiency suppresses pancreatic ductal adenocarcinoma disease progression.
Chowdhury NN; Yang Y; Dutta A; Luo M; Wei Z; Abrahams SR; Revenko AS; Shah F; Miles LA; Parmer RJ; de Laat B; Wolberg AS; Luyendyk JP; Fishel ML; Flick MJ
Mol Oncol; 2024 Jan; 18(1):113-135. PubMed ID: 37971174
[TBL] [Abstract][Full Text] [Related]
39. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.
Fan JQ; Wang MF; Chen HL; Shang D; Das JK; Song J
Mol Cancer; 2020 Feb; 19(1):32. PubMed ID: 32061257
[TBL] [Abstract][Full Text] [Related]
40. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.
Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L
J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
